Research

Hormonal

Metformin (1,500 mg) acutely increases postprandial GLP-1 secretion in patients with type 2 diabetes, contributing approximately 75% to its glucose-lowering effect via direct AMPK-dependent activation of intestinal L cells.

For patients with type 2 diabetes, taking metformin (typically 1,500 mg) with a meal triggers the release of GLP-1, a gut hormone that helps lower blood sugar. This gut-mediated effect accounts for a large portion (approx. 75%) of metformin's immediate glucose-lowering benefit. This mechanism is direct, dependent on AMPK activation in gut cells, and preserved in obese patients and those with diabetes.

GoodSupportsHIGH confidence
Metformin has a direct and AMPK-dependent effect on GLP-1–secreting L cells and increases postprandial GLP-1 secretion, which seems to contribute to metformin’s glucose-lowering effect and mode of action.
Emilie Bahne et al. · JCI Insight · 2018

Why this rating

Randomized, double-blinded, placebo-controlled clinical trial with ex vivo validation, though limited by small sample size (n=12) and acute dosing.

Source

Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes

Emilie Bahne et al. · JCI Insight · 2018

DOI 10.1172/jci.insight.93936

crossover · n=12Cited 170×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →